Human IL-28B (IFN lambda 3) Recombinant Protein

Also known as: Interleukin-28B

RUO: For Research Use Only. Not for use in diagnostic procedures.

SKU# 14-8288

Cat. No. Size
14-8288-62 5 ug
14-8288-80 25 ug
Please inquire about custom configurations or bulk packaging.

To enable ordering, please select your country. Cookies will need to be enabled to continue on our website. View our Privacy Policy.

Data for Human IL-28B (IFN lambda 3) Recombinant Protein.

Inhibition of the cytopathic effect of EMC virus in HepG2 cells by Human IL-28B Recombinant Protein....View More

  • Data for Human IL-28B (IFN lambda 3) Recombinant Protein.
Description

Description: IL-28B belongs to the IFN-λ family, a novel family of cytokines within the IL-10 superfamily. The three members of this family are IL-29 (IFN-λ1), IL-28A (IFN-λ2), and IL-28B (IFN-λ3), and are also known as the type III Interferons.

The IFN-λs signal through a heterodimeric receptor of which one subunit, IL-10R2, is shared with other members of the superfamily. The second subunit, IFN-λR1 or IL-28Rα, is unique to the IFN-λs. Signaling occurs through the Jak/STAT pathway in a similar manner as the type I IFNs (IFN-α/β) and activates many of the same genes despite low sequence homology between the cytokines and receptors in the two families. Both IFN families display antiviral activity through the induction of antiviral protein production in target cells and the upregulation of MHC class I expression. These proteins also exhibit antiproliferative and antitumor effects, making them a possible alternative to IFN-α cancer therapies. Unlike the type I IFNs, which are able to stimulate most cells, response to IFN-λ stimulation appears to be limited to dendritic and some tumor cells due to the limited expression of IFN-λR1. Another notable difference is the ability of the IFN-λ stimulation to drive dendritic cells towards the production of CD4+CD25+FoxP3+ regulatory T-cells, suggesting a possible immunoregulatory role.

Details
Reactivity Human
Purity Greater than 97%, as determined by SDS-PAGE.
Molecular Mass 20.8 kDa
Endotoxin Level Less than 0.01 ng/ug cytokine as determined by the LAL assay.
Reported Applications Cytokine Bioassays
Documentation

For complete product information, please download the TDS or IFU document.

TDS Link Download TDS
Additional Formats
Cat. No. Name Excite Emit Application Reg.
34-8288 Human IL-28B (IFN lambda 3) Recombinant Protein Carrier-Free FA RUO
References

References: Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 2010 Aug;21(4):237-51.

Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K, Thilo J, Asadullah K, Sterry W, Volk HD, Sabat R. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol. 2008 May;83(5):1181-93.

Uze G and Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie. 2007 Jun-Jul;89(6-7):729-34.

Mennechet FJ and Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood. 2006 Jun 1;107(11):4417-23.

Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol. 2005 Feb 15;174(4):1932-7